Click on the JSmol tab to take a closer look at how GLP-1 (PDB 6X18), semaglutide (PDB 7KI0), tirzepatide (PDB 7FIM), and orforglipron (PDB 6XOX) are able to stabilize the active form of the GLP-1 receptor, and compare these structures to that of the inactive GLP-1 receptor (PDB 6LN2)
The benefits of microdosing include fewer side effects, mild weight loss, and improved metabolic health, but these are largely anecdotal given the absence of scientific evidence
For instance, GLP-1RA have been tested in people with serious mental illness, who could be at a high suicidality risk, showing metabolic benefits with no increase in psychopathology or occurrence of SIS [22]
10.1016/S2213-8587(24)00318-8 136 StorgaardH.ColdF.GluudL
Disease burden and epidemiological trends of chronic kidney disease at the global, regional, national levels from 1990 to 2019
Once you open the bottle, the clock starts